N/A
N=830
Optimizing Hookah Tobacco Public Education Messages to Reduce Young Adult Use
Hookah Tobacco Smoking
Bottom Line
View on ClinicalTrials.gov: NCT04252014 ↗Enrolled (actual)
830
Serious AEs
0.0%
Results posted
Feb 2023
Primary outcome: Primary: Hookah Tobacco Initiation — 11; 5 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Hookah tobacco messages (Behavioral)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Georgetown University
- Primary completion
- Apr 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hookah Tobacco Initiation |
11; 5 | — |
| PRIMARY Hookah Tobacco Use Frequency |
2.52; 2.39 | — |
| PRIMARY Hookah Tobacco Cessation |
66; 55 | — |
| SECONDARY Hookah Tobacco Curiosity |
2.01; 1.90 | — |
| SECONDARY Motivation to Quit Smoking Hookah Tobacco |
3.82; 4.02 | — |
Summary
This is a 2-arm randomized controlled trial to test the effects of hookah tobacco public education messages among young adults who are susceptible non-users of hookah tobacco and those who are current hookah tobacco users. The primary outcomes are hookah tobacco use behavior (initiation among baseline susceptible non-users, frequency of use and cessation among baseline current users) at 6-month follow-up. Secondary outcomes are curiosity to use hookah tobacco (susceptible non-users) and motivation to quit using hookah tobacco (current hookah users) measured at 6-month follow-up. These outcomes will also be measured at 2- and 4-month follow-up time points.
Eligibility Criteria
Inclusion Criteria
- Age between 18 to 30
- Smoked hookah tobacco within the past 30 days, OR never smoked hookah tobacco and deemed susceptible to using hookah tobacco based on answers to screening questions
- Member of partnering consumer research panel conducting the study
Exclusion Criteria
- Age less than 18 or greater than 30
- Has not smoked hookah tobacco in the past 30 days OR has never smoked hookah tobacco and is not susceptible
- Not a member of partnering consumer research panel conducting the study
Data sourced from ClinicalTrials.gov (NCT04252014). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.